Table 7 Clinical trials-lenalidomide (Newly diagnosed)
From: Thalidomide and its analogues in the treatment of Multiple Myeloma
Author | Regimen(s) | Type of clinical trial | No. of pts | Best responses (>PR) | CR, nCR, VGPR | PFS/TTP/OS | Reference |
|---|---|---|---|---|---|---|---|
Rajkumar et al | Ld vs. LD | Phase III | 445 | 79% vs. 69% | CR/nCR:18% vs. 14% VGPR:33% vs. 26% | 1-year OS:96% vs. 87% | Lancet Oncol 2010 |
Zonder et al | LD vs. D | Phase III | 133 | 85% vs. 51% | NR | Not reported | ASH 2007 |
Richardson et al | LVD | Phase I/II | 35 (Phase II) | 100% | VGPR:69% CR + nCR:54% | Not reached at 19.3 months (median) | ASH 2009 |
Jakubowiak et al | LV-PLD-D | Phase I/II | 26 (Phase II) | 96% | VGPR:67% CR + nCR:33% | Not achieved at 6 months (median) | ASH 2009 |
Kumar et al | LCD vs. VCD vs. LCVD | Phase II | 117 | 90% vs. 87% vs. 94% | VGPR:33% vs. 35% vs. 42% CR:12% vs. 6% vs. 15% | Not reported | ASH 2009 |
Niesvizky et al | Clarithromycin + LD | Phase II | 72 | 90.3% | VGPR:16.7% CR + sCR:38.9% | Actuarial EFS (2yr): 85.2% (transplant), 75.2% (non-transplant) | Blood 2008 |
Palumbo et al | MPL | Phase I/II | 54 | 81% | VGPR:47.6% CR:23.8% | EFS (1 yr):92% OS (1 yr):100% | JCO 2007 |